Investing
Top Day Trader Alerts (FNM, FRE, BNVI, TRMS, VVUS, AAPL)
Published:
Last Updated:
These are this Tuesday’s top day trader and active trader alerts. We have detailed links over on each story for more detail and analysis at VSInvestor.com:
Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) are seeing a day-two rally so far, but this is the highest since October.
Bionovo, Inc. (NASDAQ: BNVI) is the next version of the daily chase in low-price micro-cap biotech stocks with any news.
Trimeris, Inc. (NASDAQ: TRMS) is down 16% after losing its buyer.
VIVUS, Inc. (NASDAQ: VVUS) is up 3% on its Qnexa NDA filing.
Apple Inc. (NASDAQ: AAPL) is up again in pre-market trading, but last night we gave a full run-down over how traders and speculators are now overly using options rather than stock to get exposure.
You can sign up and join our free email list for daily emails about analyst upgrades and downgrades, top day trading stock alerts, IPOs, secondary offerings, M&A, new ETF strategies, Warren Buffett news, and other key developments.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
